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PLipid Reduction in Adolescents
Efficacy and Safety of Coadministration
of Ezetimibe and Simvastatin in Adolescents
With Heterozygous Familial Hypercholesterolemia
Anouk van der Graaf, MD,* Cynthia Cuffie-Jackson, MD,‡ Maud N. Vissers, PHD,*
Mieke D. Trip, MD, PHD,† Claude Gagné, MD, Genming Shi, PHD,§ Enrico Veltri, MD,‡
Hans J. Avis, MD,* John J. P. Kastelein, MD, PHD*
Amsterdam, the Netherlands; Kenilworth, New Jersey; and Quebec, Canada
Objectives The study evaluated the efficacy and safety of long-term coadministration of ezetimibe and simvastatin in ado-
lescents with heterozygous familial hypercholesterolemia (HeFH).
Background Aggressive intervention to achieve lipid goals for adolescents with HeFH is recommended to reduce risk of pre-
mature cardiovascular disease.
Methods In a multicenter, randomized, double-blind, placebo-controlled study, 248 male and female subjects ages 10
and 17 years with HeFH were randomized to receive: step 1: simvastatin 10, 20, or 40 mg/day plus ezetimibe
10 mg/day or placebo for 6 weeks, followed by step 2: simvastatin 40 mg/day plus ezetimibe 10 mg/day or
placebo for 27 weeks; followed by step 3: all subjects received open-label simvastatin 10 or 20 mg/day (titrated
to maximum 40 mg/day) plus ezetimibe 10 mg/day for 20 weeks. Safety was assessed throughout the study.
Results Coadministered ezetimibe and simvastatin for 6 weeks (step 1) resulted in significantly greater mean reduction
in low-density lipoprotein cholesterol (LDL-C) from baseline (49.5%) compared with simvastatin monotherapy
(34.4%; p  0.01) in pooled dose groups and in individual dose groups (46.7% vs. 30.4%, 49.5% vs. 34.3%,
52.1% vs. 38.6%, respectively; p  0.01). At 33 weeks (step 2), ezetimibe-simvastatin subjects had a mean
54.0% reduction in LDL-C compared with a mean 38.1% reduction in simvastatin monotherapy subjects (p 
0.01). At 53 weeks (step 3), the pooled reduction in LDL-C was 49.1%. All treatment regimens were well toler-
ated throughout 53 weeks.
Conclusions Coadministration of ezetimibe with simvastatin was safe, well tolerated, and provided higher LDL-C reduction com-
pared with simvastatin alone in adolescents with HeFH studied up to 53 weeks. (Effects of Ezetimibe With Simvasta-
tin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia; NCT00129402) (J Am Coll Car-
diol 2008;52:1421–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.002d
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al dominant disorder associated with abnormally high
erum low-density lipoprotein cholesterol (LDL-C) levels
nd the risk of premature atherosclerosis and coronary heart
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ccepted September 9, 2008.isease. Although young patients may be asymptomatic, vas-
ular abnormalities, such as increased carotid intima media
hickness (IMT) (1), carotid stiffness (2), and endothelial
ysfunction (3), have been found in studies of children and
dolescents with heterozygous FH (HeFH). Because of the
igh risk of progression to premature clinical cardiovascular
isease associated with these findings, the National Cholesterol
ducation Program (NCEP), the American Heart Associa-
ion, and the American Academy of Pediatrics (AAP) recom-
end aggressive intervention and specific lipid goals for chil-
ren and adolescents with HeFH. Diet and lifestyle changes in
onjunction with lipid-lowering therapy are usually required to
chieve these goals (4–6).
An LDL-C level of 130 mg/dl is considered acceptable
nd110 mg/dl ideal for children with HeFH according to
CEP and AAP guidelines (5,7). Statin therapy has been
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improving lipid parameters, as
well as reversing vascular abnor-
malities, in children and adoles-
cents with HeFH (8–11). In
young subjects who are affected
by HeFH, however, administra-
tion of a statin with additional
lipid-lowering therapy may be re-
quired to achieve desired LDL-C
levels. Ezetimibe is a selective in-
hibitor of intestinal absorption of
cholesterol and related phytoster-
ols through interactions with the
sterol transporter Niemann-Pick
C1-Like 1, thereby reducing the
amount of cholesterol in the blood
in a complementary mechanism to
that of statins. In adults, coadmin-
istration of ezetimibe with statin
results in incremental lowering of
LDL-C levels of approximately
14% compared with statin mono-
therapy (12,13).
This phase 3 clinical trial was designed to assess whether
oadministration of ezetimibe with simvastatin provides
ncremental lowering of LDL-C and improvement in other
ipid parameters compared with simvastatin monotherapy
nder several different conditions in adolescents with
eFH. The focus of step 2 of the study was to evaluate lipid
esponses and achievement of lipid goals during coadmin-
stration of ezetimibe with simvastatin at the highest statin
ose recommended for pediatric patients (8,10). The intent
f the final, long-term portion of the study, during which
he dose of simvastatin could be titrated according to
hysician judgment, was to evaluate ezetimibe-simvastatin
oadministration under conditions that simulate normal
linical practice. The dose titration was based upon response
nd was to be in accordance with NCEP guidelines (5). An
dditional objective was to evaluate the long-term safety and
olerability of coadministration of ezetimibe and simvastatin
n this population. Compared with simvastatin mono-
herapy, coadministration of ezetimibe with simvastatin also
as the potential to allow a greater proportion of subjects to
chieve target LDL-C levels and reduction in the dose of
imvastatin while maintaining long-term safety and
olerability.
ethods
tudy population. Male and post-menarchal female ado-
escent subjects10 to17 years of age, Tanner stage II or
igher with a body weight of at least 40 kg and above the
0th percentile with HeFH were enrolled. All subjects had
o meet at least 1 of the clinical criteria for HeFH at
Abbreviations
and Acronyms
AAP  American Academy
of Pediatrics
apo B  apolipoprotein B
CPK  creatinine
phosphokinase
FH  familial
hypercholesterolemia
HDL-C  high-density
lipoprotein cholesterol
HeFH  heterozygous
familial
hypercholesterolemia
IMT  intima media
thickness
LDL-C  low-density
lipoprotein cholesterol
NCEP  National
Cholesterol Education
Program
ULN  upper limit of
normalcreening in Table 1. Hnclusion and exclusion criteria. Subjects were required to
ave a fasting triglyceride 350 mg/dl at screening and
ipid-qualifying visits and to have been on a diet in accor-
ance with AAP guidelines for children with hypercholes-
erolemia for at least 13 weeks before the lipid-qualifying
isit. Clinical laboratory values had to be within normal
imits, with baseline liver function tests and creatine phos-
hokinase1.5 the upper limit of normal (ULN). Female
ubjects could not be pregnant, and sexually active females
ere required to use adequate contraception.
Subjects were excluded from the study if they had any of
he following conditions: any cardiac disorder including
ongenital cardiac disorders or hematologic, digestive, or
entral nervous system disorders; inadequately controlled or
ewly diagnosed diabetes mellitus; uncontrolled endocrine
r metabolic disease known to influence serum lipids or
ipoproteins; known impairment of renal function or other
enal disease; active or chronic hepatobiliary or hepatic
isease; human immunodeficiency virus; known coagulopa-
hy; documented homozygous FH or laboratory values
onsistent with homozygous FH; use of LDL apheresis or
lasma apheresis; partial ileal bypass; excessive alcohol use
r drug abuse; delayed puberty. Subjects with documented
utations in the apolipoprotein B (apo B) gene in the absence
f mutations in the LDL-C receptor gene were excluded.
Concomitant therapy or prior therapy within designated
ashout periods with any of the following medications was
rohibited during the study: lipid altering drugs; oral,
ntramuscular, or intravascular corticosteroids; aspirin
reater than 325 mg/day; orlistat or sibutramine; cyclospor-
ne; and agents that interact with simvastatin, including
miodarone, verapamil, and fusidic acid.
tudy design. This was a randomized, placebo-controlled,
ulticenter, phase 3 study conducted in 3 steps. Subjects were
tratified by gender to achieve balance in the 6 arms of step 1.
uring step 1, subjects were randomized to receive double-
lind 10-, 20-, or 40-mg/day simvastatin plus placebo or
0-mg/day ezetimibe for 6 weeks. Step 2 was a double-blind
tudy of subjects who received 40-mg/day simvastatin plus
lacebo or 10-mg/day ezetimibe for 27 weeks (to week 33 of
he study). Subjects who received placebo or ezetimibe in step
continued that assignment in step 2. Step 3 consisted of an
linical Criteria for HeFH in Adolescent Patients
Table 1 Clinical Criteria for HeFH in Adolescent Patients
All Patients Had to Meet at Least 1 of the Following Criteria for HeFH
1. Genotype-confirmed HeFH and LDL-C 159 mg/dl and 400 mg/dl
2. LDL-C 159 mg/dl and 400 mg/dl and at least 1 biological parent with
genotype-confirmed HeFH and historical untreated LDL-C 159 mg/dl
3. LDL-C 159 mg/dl and 400 mg/dl and at least 1 biological parent with
untreated LDL-C of at least 210 mg/dl in the absence of another condition
associated with secondary elevated LDL-C
4. LDL-C 189 mg/dl and 400 mg/dl and a family history of
hypercholesterolemia consistent with dominant autosomal transmission
5. LDL-C 159 mg/dl and 400 mg/dl and tendinous xanthomas, without
another condition associated with secondary elevated LDL-CeFH  heterozygous familial hypercholesterolemia; LDL-C  low-density lipoprotein cholesterol
o
2
d
D
4
d
a
S
c
p
a
p
t
C
s
g
s
g
m
u
p
t
s
w
u
o
p
l
w
a
L
h
t
(
a
c
n
g
r
f
p
u
1423JACC Vol. 52, No. 17, 2008 van der Graaf et al.
October 21, 2008:1421–9 Ezetimibe/Simvastatin in Adolescents With HeFHpen-label regimen during which all subjects received 10- or
0-mg/day simvastatin (based on physician judgment of initial
ose) plus 10-mg/day ezetimibe for 20 weeks (to week 53).
uring step 3, simvastatin doses could be titrated up to 20 or
0 mg/day to reach individualized LDL-C goals or down as
etermined by investigators’ judgment. All medications were
dministered orally in the evening.
tudy end points. The primary end point was percent
hange from baseline in LDL-C in the pooled simvastatin
lus ezetimibe versus pooled simvastatin monotherapy groups
fter 6 weeks of treatment (step 1). The key secondary end
oints included comparison of other lipid parameters, such as
otal cholesterol, high-density lipoprotein cholesterol (HDL-
), non–HDL-C, triglycerides, and apo B in the pooled
imvastatin plus ezetimibe versus simvastatin monotherapy
roups after 6 weeks. Reductions in LDL-C in the individual
imvastatin (10, 20, and 40 mg/day) plus ezetimibe 10-mg/day
roups and individual simvastatin (10, 20, and 40 mg/day)
onotherapy groups were also compared after 6 weeks. Eval-
ation of all lipid parameters and analysis of comparative
ercentages of subjects who reached recommended LDL-C
Figure 1 Study Design
Study design and subject disposition throughout study.reatment goals in coadministered ezetimibe-simvastatin and cimvastatin monotherapy groups after 33 weeks (end of step 2)
ere other secondary end points.
Safety and tolerability were assessed throughout the study
sing physical examination, electrocardiograms, assessment
f sexual maturation and growth, monitoring of menstrual
eriods for female subjects, adverse event reports, and
aboratory assessments. A treatment-emergent adverse event
as an adverse event that began after randomization and/or
fter any increase in intensity of therapy during the study.
aboratory investigations included safety and lipid panels,
ormone assessments, thyroid function tests, and pregnancy
ests for female subjects. Safety panels included hematology
differential, white blood cells, platelet counts, hemoglobin,
nd hematocrit); blood chemistries (total protein, albumin,
alcium, inorganic phosphorus, fasting glucose, blood urea
itrogen, uric acid, total bilirubin, alkaline phosphatase, serum
lutamic pyruvic transaminase/alanine aminotransferase, se-
um glutamic oxaloacetic transaminase/aspartate aminotrans-
erase, serum creatinine, serum electrolytes, creatinine phos-
hokinase (CPK), and gamma-glutamyl transpeptidase), and
rinalysis (specific gravity, pH, blood, ketones, protein, glu-
ose, and microscopic evaluation of white and red blood cells).
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Ezetimibe/Simvastatin in Adolescents With HeFH October 21, 2008:1421–9tatistical analysis. In each of the 6 treatment groups 30
atients were needed for the study to have a power of 90%
o detect a difference of 7% in LDL-C between the pooled
reatment groups (ezetimibe plus simvastatin versus simva-
tatin monotherapy) at 6 weeks with a 2-sided alpha of 0.05,
ssuming a common standard deviation of 14%.
Analysis of the primary end point, percent change from
aseline in LDL-C at 6 weeks (end of step 1), was performed
sing an analysis of variance model with fixed effects for
imvastatin dose (simvastatin 10, 20, and 40 mg), treatment
ezetimibe, placebo), simvastatin dose by treatment interaction,
nd gender. The poolability across the doses of simvastatin was
ssessed using the test of interaction. If the primary comparison
f pooled ezetimibe-simvastatin groups versus pooled simva-
tatin monotherapy groups was significant, pairwise compari-
ons in groups who received individual doses of simvastatin
lus ezetimibe versus the corresponding simvastatin mono-
herapy doses were performed. The primary end point was also
valuated for pre-specified subgroups including sex, race, base-
ine triglyceride, baseline LDL-C, and baseline HDL-C.
Comparisons of percent change from baseline in total
holesterol, non–HDL-C, apo B, and HDL-C at 6 weeks
ere univariately evaluated using a similar approach as the
rimary efficacy variable. Due to the large variability asso-
iated with triglycerides noted in the literature, a nonpara-
etric approach was used for the percent change from
aseline in triglycerides at 6 weeks. The Hochberg’s proce-
ure was implemented for these comparisons to control the
verall type I error of 0.05. For the analyses at 33 weeks (end
f step 2), an analysis of variance model with fixed effects for
reatment and gender were performed for the percent
hange from baseline in LDL-C, HDL-C, total cholesterol,
on–HDL-C, apo B, and a nonparametric approach was
sed for the percent change from baseline in triglycerides.
he proportion of subjects who reached the recommended
DL-C treatment goal from baseline to 33 weeks was
valuated using a chi-square test.
Safety and tolerability evaluations included all randomized
atients. The safety data, including adverse events, laboratory
afety parameters, growth and development parameters, were
ummarized descriptively by each treatment group.
esults
ubject characteristics. The study design and disposition
f all subjects who were screened for this study are shown in
igure 1. Randomization of 248 eligible subjects for step 1
roduced 6 treatment groups and pooled ezetimibe-
imvastatin and simvastatin monotherapy groups that were
ell balanced for age, race, baseline LDL-C, and disease
haracteristics (Table 2).
xtent of exposure. The extent of exposure, as measured by
uration of any treatment during the study, was a mean of 228
ays and ranged from 13 days to a maximum of 395 days. (fficacy of coadministration of ezetimibe and simvastatin.
he percent change from baseline in LDL-C after 6 weeks
f treatment in the pooled simvastatin groups with
zetimibe compared with simvastatin monotherapy groups,
he primary end point for this study, showed a significantly
reater reduction in LDL-C in subjects who received
oadministered ezetimibe and simvastatin compared with
hose who received simvastatin alone (p  0.01) (Table 3).
imilar differences between the respective pooled groups in
otal cholesterol reductions (p  0.01), non–HDL-C lipids
aseline Demographic and Disease Characteristicsor All Randomized Subjects n Steps 1 and 2
Table 2 Baseline Demographic and Disease Characteristicsfor All Randomized Subjects in Steps 1 and 2
Pooled EZESIM
Groups
(n  126)
Pooled SIM
Monotherapy Groups
(n  122)
Gender, n (%)
Female 53 (42) 53 (43)
Male 73 (58) 69 (57)
Race, n (%)
White 105 (83) 98 (80)
Asian 5 (4) 4 (3)
Black or African American 3 (2) 1 (1)
Multiracial 13 (10) 19 (16)
Age, yrs
Mean (SD) 14.0 (1.9) 14.3 (1.8)
Median 14.0 14.0
Range 10–17 10–17
Baseline LDL-C, mg/dl
Mean (SD) 225.2 (41.7) 218.6 (44.1)
Median 217.8 207.0
Range 160.5–351.0 148.5–336.0
Baseline NCEP cardiovascular risk
categories, n (%)
CHD
No 126 (100) 122 (100)
Other forms of atherosclerosis*
No 126 (100) 122 (100)
Diabetes
No 126 (100) 122 (100)
Cigarette smoking in previous
month
Yes 1 (1) 12 (10)
No 125 (99) 110 (90)
Family history of premature CHD†
Yes 50 (40) 46 (38)
No 76 (69) 76 (62)
Hypertension‡
No 126 (100) 122 (100)
HDL-C value, mg/dl
40 27 (21) 25 (20)
40–49 61 (48) 58 (48)
50–59 29 (23) 31 (25)
60 9 (7) 8 (7)
Peripheral artery disease, abdominal aortic aneurysm, symptomatic carotid artery disease,
ransient ischemic attack, stroke. †Coronary heart disease in male first-degree relative55 years
ld or CHD in female first-degree relative 65 years old. ‡Blood pressure 140/90 mm Hg or on
ntihypertensive medication.
CHD  coronary heart disease; EZE  ezetimibe; HDL-C  high-density lipoprotein cholesterol;
CEP  National Cholesterol Education Program; SIM  simvastatin.p 0.01), and apo B levels (p 0.01) were also observed.
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October 21, 2008:1421–9 Ezetimibe/Simvastatin in Adolescents With HeFHo significant differences in HDL-C increases (p 
.95) or decreased triglyceride levels (p  0.48) between
he respective groups were observed at 6 weeks. The test
or simvastatin dose by treatment interaction was not
ignificant (p  0.79, 0.52, 0.80, and 0.91 for LDL-C,
on–HDL-C, apo B, and HDL-C, respectively), which
uggests that it is appropriate to pool across the doses of
imvastatin. Subgroup analysis revealed no significant
ifferences in LDL-C reductions according to gender,
ace, baseline triglycerides (/ median), baseline
DL-C (/ median), or baseline HDL-C (/ me-
ian) by the end of step 1 (Table 4).
Percent changes in LDL-C levels from baseline at the
nd of step 1 in the pooled and individual dosing groups are
LDL-C and Other Lipid Parameters in Pooled Ezeand Simvastatin Monotherapy G oups at Baselin
Table 3 LDL-C and Other Lipid Parameters iand Simvastatin Monotherapy Grou
Parameter
Pooled EZE
Group
LDL-C baseline
No. patients 126
Mean actual level, mg/dl 225.36
LDL-C at step 1 end point
Mean actual level, mg/dl 114.10
Mean % change 49.45
Total cholesterol baseline
No. of patients 126
Mean actual level, mg/dl 292.20
Total cholesterol at step 1 end point
Mean actual level, mg/dl 179.84
Mean % change 38.23
Non–HDL-C baseline
No. of patients 126
Mean actual level, mg/dl 245.87
Non–HDL-C at step 1 end point
Mean actual level, mg/dl 130.84
Mean % change 46.84
HDL-C baseline
No. of patients 126
Mean actual level, mg/dl 46.34
HDL-C at step 1 end point
Mean actual level, mg/dl 49.00
Mean % change 6.58
Triglyceride baseline†
No. of patients 126
Median actual level, mg/dl 89.00
Triglyceride at step 1 end point†
Median actual level, mg/dl 74.00
Median % change 16.56
Apo B baseline
No. of patients 120
Mean actual level, mg/dl 177.96
Apo B at step 1 end point
Mean actual level, mg/dl 108.29
Mean % change 38.92
*Patients not having at least 1 post-baseline value were not included
range)/1.075 are provided. The p values are based on nonparametric
Apo B  apolipoprotein B; other abbreviations as in Tables 1 and 2hown in Figure 2. Coadministration of ezetimibe with 10-, c0-, or 40-mg simvastatin compared with simvastatin
onotherapy resulted in differences of 46.7% versus
30.4%, 49.5% versus 34.3%, and 52.1% versus
38.6% from baseline, respectively (p  0.01 for all
omparisons), resulting in incremental differences between
roups of 16.3%, 15.2%, and 13.6%, respectively. Similar
eductions were found in pairwise comparisons of total
holesterol, non–HDL-C, and apo B in the individual
imvastatin dosing groups that received ezetimibe or placebo.
At the end of step 2 (week 33), lipid parameters in
ubjects in the coadministration of ezetimibe with 40-mg
imvastatin group compared with the 40-mg simvastatin
onotherapy group showed significant incremental lower-
ng of LDL-C (15.9% difference between groups), total
e Plus Simvastatind at the Step 1 End Point
led Ezetimibe Plus Simvastatin
Baseline and at the Step 1 End Point
Pooled SIM Monotherapy
Groups* p Value
120
219.41 3.90 0.27
144.08 3.59 0.01
34.43 1.22 0.01
120
285.63 4.11 0.25
210.15 3.76 0.01
26.28 0.99 0.01
120
239.66 4.14 0.28
161.42 3.76 0.01
32.68 1.16 0.01
120
45.97 0.84 0.75
48.78 0.89 0.86
6.47 1.19 0.95
120
88.00 38.84 0.88
75.50 40.47 0.73
12.28 31.49 0.48
118
170.98 2.92 0.09
125.27 2.59 0.01
26.69 1.11 0.01
riglycerides, median and standard deviation derived by (interquartile
is of variance on the ranks extracting treatment and gender effects.timibe an
n Poo
ps at
SIM
s
3.80
3.50
1.19
4.01
3.67
0.96
4.05
3.68
1.13
0.82
0.87
1.16
49.30
35.35
30.26
2.87
2.57
1.10
. †For tholesterol (13.2% difference), non–HDL-C (15.6% differ-
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Ezetimibe/Simvastatin in Adolescents With HeFH October 21, 2008:1421–9nce), and apo B (14.8% difference) with coadministration
Table 5). Significantly more subjects had achieved NCEP/
AP acceptable (130 mg/dl) and ideal (110 mg/dl)
DL-C levels in the coadministration of ezetimibe with
0-mg simvastatin group than in the simvastatin 40-mg
onotherapy group (p  0.01 for both comparisons) by the
nd of step 2. Again, no significant differences in increased
DL-C levels were observed (p  0.58), but median
riglyceride levels had decreased significantly in the coad-
inistered ezetimibe-simvastatin group (9.5% difference)
ompared with the simvastatin monotherapy group (p 
.01) (Table 5).
Figure 2 Step 1 (6 Weeks) Reduction in LDL-C From Baseline
Changes from baseline in LDL-C in subjects who received coadministered
ezetimibe with 10-, 20-, or 40-mg simvastatin (solid bars) or 10-, 20-, or 40-mg
simvastatin (open bars) monotherapy after 6 weeks (step 1). *p  0.01 com-
pared with monotherapy group.
Subgroup Analysis of Changes From Baseline inPlus Simvast tin Group d Pooled Simvastat
Table 4 Subgroup Analysis of Changes FromPlus Simvastatin Group and Pooled
Subgroup
Pooled EZE
N
Mean L
(SE
Gender
Male 73 49
Female 53 49
Race
Caucasian 105 48
Non-Caucasian 21 52
Baseline LDL-C
Median* 57 50
Median* 69 48
Baseline HDL-C
Median† 61 47
Median† 65 50
Baseline triglycerides
Median‡ 61 51
Median‡ 65 47
*Median baseline LDL-C  212.5 mg/dl. †Median baseline HDL-C 
SE  standard error; other abbreviations as in Tables 1 and 2.aAt week 53, the mean percent change in LDL-C in the
verall population (n 200 at end of study) was49.1% from
aseline. Mean percent changes were 38.5% in total choles-
erol, 46.4% in non–HDL-C, and median percent changes
f 16.6% were observed in triglycerides. The HDL-C levels
ere 3.3% above baseline levels at the end of step 3 (Table 6).
afety. Treatment-emergent adverse events that were re-
orted by the end of step 2 (33 weeks total) in 5% or more
f subjects in the pooled ezetimibe with simvastatin and
imvastatin monotherapy groups are shown in Table 7. Both
reatment regimens were well tolerated. Treatment-
mergent adverse events occurred in 105 subjects (83%) in
he coadministered ezetimibe plus simvastatin group and in
03 subjects (84%) in the simvastatin monotherapy group.
y the end of step 3 (53 weeks), treatment-emergent
dverse events were reported in 168 subjects (71%) in the
tudy overall. Influenza (8%), nasopharyngitis (17%), and
eadache (9%) were the only treatment-emergent adverse
vents that were reported in more than 5% of subjects. No
eaths occurred during the study.
There were 6 subjects who had consecutive transaminase
levations of at least 3 ULN during the study (1 subject in
he ezetimibe with 20-mg simvastatin group, 2 cases in the
zetimibe with 40-mg simvastatin group, 2 in the 40-mg
imvastatin monotherapy group, and 1 additional case
uring step 3). Maximum post-baseline levels of alanine
minotransferase and aspartate aminotransferase in patients
ho had 2 consecutive levels of 3 ULN ranged from 92
o 316 mU/ml (reference range: 5 to 25 mU/ml) and 102 to
57 mU/ml (reference range: 8 to 30 mU/ml), respectively.
ll elevated alanine aminotransferase and aspartate amino-
ransferase values resolved with interruption or discontinu-
C in the Pooled Ezetimibep at t End of St p 1
eline in LDL-C in the Pooled Ezetimibe
astatin Group at the End of Step 1
Pooled SIM Monotherapy
Change
/dl) N
Mean LDL-C Change
(SE) (mg/dl)
1.52 69 33.71 1.39
2.15 51 35.51 1.97
1.44 96 33.66 1.35
2.18 24 37.73 1.99
1.63 63 36.23 1.60
1.87 57 32.53 1.64
1.72 56 33.12 1.80
1.82 64 35.66 1.48
1.56 61 34.89 1.59
1.94 59 34.04 1.69
g/dl. ‡Median baseline triglycerides  88.5 mg/dl.LDL-Grou
Bas
Simv
SIM
DL-C
) (mg
.44
.32
.79
.43
.07
.84
.70
.98
.26
.64tion of therapy.
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ssociated muscle symptoms. No subject had CPK elevations
5 ULN with associated muscle symptoms. Of the 2
atients with any CPK value 10 ULN, 1 female subject
ad an isolated maximum value of 19,530 mU/ml (reference
ange: 20 to 120 mU/ml) on day 232 during step 2 treatment
ith ezetimibe 10 mg/day and simvastatin 40 mg/day. Her
PK value returned to within the reference range 7 days later
pon interruption of treatment. She subsequently continued in
he study for 371 days of treatment without recurrent eleva-
ions in CPK levels. One male subject had a maximum value of
Lipid Parameters at the End of Step 2 (33 WeekEzetimibe Plus Simvastati 40-mg Group and Si
Table 5 Lipid Parameters at the End of StepEzetimibe Plus Simvastatin 40-mg G
Parameter EZE
LDL-C baseline
No. of patients
Mean actual level, mg/dl
LDL-C step 2 end point
Mean actual level, mg/dl
Mean % change
Total cholesterol baseline
No. of patients
Mean actual level, mg/dl
Total cholesterol at step 2 end point
Mean actual level, mg/dl
Mean % change
Non–HDL-C baseline
No. of patients
Mean actual level, mg/dl
Non–HDL-C at step 2 end point
Mean actual level, mg/dl
Mean % change
HDL-C baseline
No. of patients
Mean actual level, mg/dl
HDL-C at step 2 end point
Mean actual level, mg/dl
Mean % change
Triglyceride baseline*
No. of patients
Median actual level, mg/dl
Triglyceride at step 2 end point*
Median actual level, mg/dl
Median % change
Apo B baseline
No. of patients
Mean actual level, mg/dl
Apo B at step 2 end point
Mean actual level, mg/dl
Mean % change
Subjects achieving AAP acceptable LDL-C goal
(130 mg/dl), n (%)
Subjects achieving AAP ideal LDL-C goal
(110 mg/dl), n (%)
*For triglycerides, median and standard deviation derived by (interqu
analysis of variance on the ranks extracting treatment and gender eff
AAP  American Academy of Pediatrics; other abbreviations as in,666 mU/ml (reference range: 30 to 180 mU/ml) on day 47 nuring step 1 treatment with ezetimibe 10 mg/day and sim-
astatin 20 mg/day. His CPK value returned to 214 mU/ml on
ay 63 after discontinuation of treatment.
Eight subjects reported myalgia (7 who received ezetimibe
ith simvastatin vs. 1 who received simvastatin monotherapy).
n these 8 patients, CPK levels were unremarkable and no
ubject with myalgia had CPK values of 3 ULN.
There were no clinically significant adverse effects on
rowth, as assessed by measurement of height and weight;
exual maturation, as assessed by clinical examination; or
teroid hormones, as assessed by clinical review of the
tatin 40-mg Group
3 Weeks) in
and Simvastatin 40-mg Group
40-mg Group SIM 40-mg Group p Value
126 120
3 3.86 219.27 3.95 0.25
7 3.65 134.60 3.69 0.01
9 1.41 38.14 1.43 0.01
126 120
3 4.05 285.47 4.15 0.23
2 3.75 200.20 3.79 0.01
5 1.15 29.25 1.17 0.01
126 120
5 4.06 239.51 4.19 0.25
7 3.83 152.67 3.87 0.01
1 1.37 35.73 1.38 0.01
126 120
7 0.82 45.96 0.84 0.79
6 0.86 47.47 0.87 0.87
7 1.27 3.68 1.28 0.58
126 120
0 49.30 88.00 38.84 0.88
0 38.14 81.00 39.07 0.01
0 23.76 13.04 39.00 0.01
122 118
1 2.91 170.83 2.96 0.07
5 2.72 122.08 2.79 0.01
4 1.39 27.88 1.43 0.01
(77) 64 (53) 0.01
(63) 32 (27) 0.01
nge)/1.075 are provided. The p values are based on nonparametric
, 2 and 3.s) inmvas
2 (3
roup
SIM
225.6
103.4
53.9
292.4
167.0
42.4
246.1
119.3
51.3
46.2
47.6
4.6
89.0
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20.0
178.3
101.2
42.6
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ortisol, dehydroepiandrosterone, follicle-stimulating hor-
one, and luteinizing hormone levels in all subjects).
imilar changes in weight and height were found in groups
ho were randomized to receive ezetimibe with simvastatin
r simvastatin monotherapy for steps 1 and 2 (Table 8).
urthermore, no trends in changes in menstrual cycle
uration were associated with either treatment regimen, and
ormone levels were generally similar between treatment
roups (data not shown).
In 238 subjects who received coadministration of
zetimibe plus simvastatin during the study (up to 53
eeks), only 7 (3%) discontinued treatment because of
dverse events. Adverse events leading to discontinuation
ere myalgia and increased alanine aminotransferase in 2
ubjects each (1%) and nausea, increased blood CPK, and
ipid Parameters at the End oftep 3 (53 W eks) in the Overall Population
Table 6 Lipid Parameters at the End ofStep 3 (53 Weeks) in the Overall Population
Parameter EZESIM
LDL-C baseline
No. of patients 246
Mean actual level, mg/dl 222.10 2.75
LDL-C end point
No. of patients 200
Mean actual level, mg/dl 112.44 2.76
Mean % change 49.13 1.09
Total cholesterol baseline
No. of patients 246
Mean actual level, mg/dl 288.34 2.89
Total cholesterol end point
No. of patients 200
Mean actual level, mg/dl 175.93 2.90
Mean % change 38.54 0.91
Non–HDL-C baseline
No. of patients 246
Mean actual level, mg/dl 242.46 2.91
Non–HDL-C end point
No. of patients 200
Mean actual level, mg/dl 129.18 2.93
Mean % change 46.42 1.07
HDL-C baseline
No. of patients 246
Mean actual level, mg/dl 45.88 0.59
HDL-C end point
No. of patients 200
Mean actual level, mg/dl 46.75 0.71
Mean % change 3.32 1.16
Triglyceride baseline*
No. of patients 246
Median actual level, mg/dl 88.50 40.91
Triglyceride end point*
No. of patients 200
Median actual level, mg/dl 75.50 37.00
Median % change 16.63 43.50
For triglycerides, median and standard deviation derived by (interquartile range)/1.075 are
rovided.
Abbreviations as in Tables 1 and 2.uscle spasms in 1 subject each (1%). Aiscussion
e show that, consistent with studies of ezetimibe coad-
inistration with simvastatin in adults, significant incre-
ental decreases of approximately 15% in LDL-C levels
ompared with administration of simvastatin alone were
chieved within 6 weeks of treatment. These decreases were
ustained throughout the subsequent 26-week, double-blind
reatment-Emergent Adverse Events Occurring in% or More of Subjects Through the End of Step 233 Weeks Total) in the Po led Ezetimibe Plusimvasta in 40-mg Group and Pool d Simvas ati0-mg Group
Table 7
Treatment-Emergent Adverse Events Occurring in
5% or More of Subjects Through the End of Step 2
(33 Weeks Total) in the Pooled Ezetimibe Plus
Simvastatin 40-mg Group and Pooled Simvastatin
40-mg Group
Adverse Event (n, %)
Pooled EZESIM
40 mg
(n  126)
Pooled SIM
40 mg
(n  122)
Any 105 (83) 103 (84)
Gastrointestinal
Abdominal pain 6 (5) 3 (2)
Diarrhea 9 (7) 3 (2)
Nausea 8 (6) 4 (3)
Vomiting 5 (4) 6 (5)
Infections and infestations
Influenza 8 (6) 12 (10)
Nasopharyngitis 27 (21) 27 (22)
Sinusitis 6 (5) 5 (4)
Investigations
ALT increased* 6 (5) 3 (2)
Musculoskeletal and connective tissue
Myalgia 7 (6) 1 (1)
Nervous system
Headache 16 (13) 16 (13)
Respiratory/thoracic/mediastinal
Cough 4 (3) 8 (7)
Pharyngolaryngeal pain 6 (5) 3 (2)
Skin and subcutaneous tissue
Acne 4 (3) 9 (7)
It should be noted that some elevations in ALT/AST may have been reported as adverse events by
ndividual investigators without reaching the level of consecutive elevations of 3 upper limit of
ormal.
ALT  alanine aminotransferase; AST  aspartate aminotransferase; other abbreviations as in
able 2.
eight and Weight Changes in Adolescent Subjectsith HeFH ho Received Coadministration ofzetimibe Wit Simvastatin r Simva tatinono herapy
Table 8
Height and Weight Changes in Adolescent Subjects
With HeFH Who Received Coadministration of
Ezetimibe With Simvastatin or Simvastatin
Monotherapy
Pooled EZESIM
Groups
(n  126)
Pooled SIM
Monotherapy Groups
(n  122)
Mean baseline weight, kg 58.1 12.9 61.0 15.7
Change at end of step 2, kg 2.8 3.7 2.8 3.3
Change at end of step 3
(all patients), kg
61.6  13.1
Changes in height, % of patients
0 to 10% change in height
at end of step 2
88 87
0 to 10% change in height at
end of step 3 (all patients)
94bbreviations as in Tables 1 and 2.
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rolonged reductions were maintained through 53 weeks in
he overall study population. Significantly greater reductions
rom baseline in total cholesterol, non–HDL-C, and apo B
evels were also documented after 6 weeks and again at 33
eeks in subjects who received coadministration of
zetimibe with simvastatin compared with simvastatin
onotherapy. These parameters also remained at reduced
evels throughout the final 20-week phase of the study.
Mean incremental LDL-C reductions associated with
oadministration of ezetimibe were consistent across the
0-, 20-, and 40-mg simvastatin dosing groups after 6
eeks of treatment and significantly more subjects had
eached NCEP/AAP recommended LDL-C goals in the
oadministration group than in the monotherapy group by
he end of 33 weeks. These results suggest that ezetimibe
oadministration may help more adolescent subjects with
eFH reach their lipid goals, as well as allow lower doses of
imvastatin to be used. Achievement of specific lipid goals
n adolescence has not been demonstrated to provide long-
erm reduction in cardiovascular risk for patients with
eFH in this study and requires further work to establish
arget lipid goals as they relate to long-term outcome.
owever, initiation of intervention for dyslipidemias by
ediatricians with specific lipid goals for pediatric patients
ave been recommended by expert opinion (4,5) and are useful
n clinical practice to assess progress and efficacy of therapy.
There were no important differences between groups in
reatment-emergent adverse events or serious adverse
vents, suggesting no additional toxicity associated with
zetimibe coadministration with simvastatin compared with
imvastatin monotherapy. Although the study was not
owered to detect significant differences between groups in
afety parameters, these data as well as the low rates of
iscontinuation in all 3 phases of the study are promising
ith respect to tolerability and safety of these agents in this
opulation. These considerations are important for this
opulation, whose exposure to lipid abnormalities is lifelong
nless treatment is consistently maintained. Previous work
uggests that the timing of treatment of dyslipidemias with
tatins in children is an independent predictor of carotid
MT within 5 years, suggesting that earlier exposure to
reatment delays progression of carotid IMT compared with
ater initiation of treatment (11). Increasing the exposure to
ow levels of cholesterol by the addition of ezetimibe to
tatin therapy in young patients would be expected to
rovide additional benefit. Further work in the context of
ptimized lipid-lowering therapy, using carotid IMT mea-
urements and other markers, is needed to evaluate long-
erm benefits for these high-risk patients.
We conclude that coadministration of ezetimibe with
imvastatin was significantly more efficacious for reducing
DL-C levels and improving lipid profiles than simvastatin
onotherapy in adolescent subjects with HeFH. Regimens
f ezetimibe with simvastatin were well tolerated. Coad-
inistration of ezetimibe may be considered an important preatment strategy for adolescent patients 10 to 17 years of
ge with HeFH who require a statin plus adjunctive therapy
o reach recommended LDL-C goals.
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